Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Dekem1/Cya
Common Name:
Dek-KO
Product ID:
S-KO-00729
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Dek-KO
Strain ID
KOCMP-110052-Dek-B6J-VB
Gene Name
Dek
Product ID
S-KO-00729
Gene Alias
1810019E15Rik; D13H6S231E
Background
C57BL/6JCya
NCBI ID
110052
Modification
Conventional knockout
Chromosome
13
Phenotype
MGI:1926209
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Dekem1/Cya mice (Catalog S-KO-00729) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000021807
NCBI RefSeq
NM_025900
Target Region
Exon 3~5
Size of Effective Region
~2.6 kb
Detailed Document
Click here to download >>
Overview of Gene Research
DEK, a highly conserved nuclear factor, is an oncogene [5,8]. It was initially discovered as fused with the NUP214 gene in some acute myeloid leukemia patients, forming the DEK-NUP214 oncoprotein [5,8,9]. DEK is highly expressed in most human tissues and overexpressed in numerous cancers, and is involved in epigenetic and transcriptional regulation, as well as multiple cellular processes like self-renewal, proliferation, differentiation, senescence, and apoptosis [8]. Secreted DEK can act as a hematopoietic cytokine, regulating hematopoiesis by activating signaling through the CXCL2 receptor, enhancing hematopoietic stem cell proliferation and reducing hematopoietic progenitor cell numbers [7].

In the context of head and neck carcinomas, a novel DEK::AFF2 fusion carcinoma has been described. These tumors occur in multiple head and neck sites, show aggressive behavior with local recurrence, lymph node, and distant metastasis [1,2,3,6]. In sinonasal and skull base non-keratinizing squamous cell carcinomas, RNA sequencing identified DEK-AFF2 fusions in a significant proportion of cases. Histologically, they have distinct features and overlap with some benign and malignant tumors, but are confirmed as aggressive malignancies despite their relatively bland histology [2]. In squamous cell carcinoma (SCC), DEK plays important roles in disease progression and is a potential therapeutic target, especially for HPV-associated SCC, though the mechanism remains unclear [5]. In asthma, DEK deficiency alleviates airway inflammation by down-regulating PINK1-Parkin mitophagy, NLRP3 inflammasome activation, and apoptosis, likely through the DEK/ATAD3A/DRP1 signaling axis [4].

In summary, DEK is an oncogene involved in diverse biological processes and disease conditions. Its role in diseases such as leukemia, head and neck carcinomas, SCC, and asthma has been revealed through various studies. Understanding DEK's functions, especially through gene-knockout or conditional-knockout models as in the asthma study [4], can provide insights into disease mechanisms and potential therapeutic targets.

References:

1. Ruangritchankul, Komkrit, Sandison, Ann. 2022. DEK::AFF2 Fusion Carcinomas of Head and Neck. In Advances in anatomic pathology, 30, 86-94. doi:10.1097/PAP.0000000000000376. https://pubmed.ncbi.nlm.nih.gov/36221219/

2. Rooper, Lisa M, Agaimy, Abbas, Dickson, Brendan C, Weinreb, Ilan, Bishop, Justin A. . DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity. In The American journal of surgical pathology, 45, 1682-1693. doi:10.1097/PAS.0000000000001741. https://pubmed.ncbi.nlm.nih.gov/34049316/

3. Amin, Sara E, Lewis, James S, Bridge, Julia A, Bishop, Justin A, Saluja, Karan. 2024. DEK::AFF2 Fusion-Associated Squamous Cell Carcinoma: A Case Series with Literature Review on an Emerging and Challenging Entity. In Head and neck pathology, 18, 86. doi:10.1007/s12105-024-01690-x. https://pubmed.ncbi.nlm.nih.gov/39312022/

4. Bai, Qiaoyun, Liu, Ruobai, Quan, Changlin, Song, Yilan, Yan, Guanghai. 2024. DEK deficiency suppresses mitophagy to protect against house dust mite-induced asthma. In Frontiers in immunology, 14, 1289774. doi:10.3389/fimmu.2023.1289774. https://pubmed.ncbi.nlm.nih.gov/38274803/

5. Ishida, Kazuhisa, Nakashima, Takayuki, Shibata, Toshiyuki, Hara, Akira, Tomita, Hiroyuki. 2020. Role of the DEK oncogene in the development of squamous cell carcinoma. In International journal of clinical oncology, 25, 1563-1569. doi:10.1007/s10147-020-01735-5. https://pubmed.ncbi.nlm.nih.gov/32656741/

6. Rivera, Jonathan P, Kuo, Ying-Ju, Hang, Jen-Fan. 2024. DEK::AFF2 Carcinoma of the Sinonasal Tract and Skull Base: A Comprehensive Review. In Surgical pathology clinics, 17, 587-597. doi:10.1016/j.path.2024.07.008. https://pubmed.ncbi.nlm.nih.gov/39489551/

7. Bodine, David M. 2019. All hands on DEK. In The Journal of clinical investigation, 129, 2205-2206. doi:10.1172/JCI128986. https://pubmed.ncbi.nlm.nih.gov/31107244/

8. Sandén, C, Gullberg, U. 2015. The DEK oncoprotein and its emerging roles in gene regulation. In Leukemia, 29, 1632-6. doi:10.1038/leu.2015.72. https://pubmed.ncbi.nlm.nih.gov/25765544/

9. Panagopoulos, Ioannis, Gorunova, Ludmila, Torkildsen, Synne, Micci, Francesca, Heim, Sverre. . DEK-NUP214-Fusion Identified by RNA-Sequencing of an Acute Myeloid Leukemia with t(9;12)(q34;q15). In Cancer genomics & proteomics, 14, 437-443. doi:. https://pubmed.ncbi.nlm.nih.gov/29109093/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest